KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Income: 2018-2024

Historic Non Operating Income for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $38.4 million.

  • Royalty Pharma's Non Operating Income fell 76.07% to $17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.0 million, marking a year-over-year decrease of 235.13%. This contributed to the annual value of $38.4 million for FY2024, which is 81.55% down from last year.
  • As of FY2024, Royalty Pharma's Non Operating Income stood at $38.4 million, which was down 81.55% from $207.9 million recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Non Operating Income registered a high of $207.9 million during FY2023, and its lowest value of -$189.5 million during FY2021.
  • For the 3-year period, Royalty Pharma's Non Operating Income averaged around $56.4 million, with its median value being $38.4 million (2024).
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 277.86% in 2021, then soared by 370.05% in 2023.
  • Yearly analysis of 5 years shows Royalty Pharma's Non Operating Income stood at $106.6 million in 2020, then tumbled by 277.86% to -$189.5 million in 2021, then skyrocketed by 59.37% to -$77.0 million in 2022, then spiked by 370.05% to $207.9 million in 2023, then plummeted by 81.55% to $38.4 million in 2024.